Amphastar Pharmaceuticals (AMPH)
(Delayed Data from NSDQ)
$47.57 USD
+1.28 (2.77%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $47.56 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$47.57 USD
+1.28 (2.77%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $47.56 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum B VGM
Zacks News
Should Janus Henderson Small Cap Growth Alpha ETF (JSML) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JSML
Amphastar Pharmaceuticals (AMPH) Laps the Stock Market: Here's Why
by Zacks Equity Research
In the closing of the recent trading day, Amphastar Pharmaceuticals (AMPH) stood at $55.61, denoting a +1.85% change from the preceding trading day.
Amphastar Pharmaceuticals (AMPH) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Amphastar Pharmaceuticals (AMPH) closed at $52.35, marking a -0.85% move from the previous day.
Amphastar Pharmaceuticals (AMPH) Falls More Steeply Than Broader Market: What Investors Need to Know
by Zacks Equity Research
In the most recent trading session, Amphastar Pharmaceuticals (AMPH) closed at $54.94, indicating a -0.81% shift from the previous trading day.
The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Abercrombie & Fitch, Cameco, CyberArk Software and LendingTree
by Zacks Equity Research
Amphastar Pharmaceuticals, Abercrombie & Fitch, Cameco, CyberArk Software and LendingTree are part of the Zacks top Analyst Blog.
5 Top Growth Stocks to Buy as Recession Fears Subside
by Tirthankar Chakraborty
Invest in growth stocks such as Amphastar Pharmaceuticals (AMPH), Abercrombie & Fitch (ANF), Cameco (CCJ), CyberArk Software (CYBR) and LendingTree (TREE) as the U.S. economy defies recession fears.
Zacks Industry Outlook Highlights Amphastar, Teva and Dr. Reddy's
by Zacks Equity Research
Amphastar, Teva and Dr. Reddy's have been highlighted in this Industry Outlook article.
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
by Sundeep Ganoria
With the ease in inflationary pressure, the Zacks Medical - Generic Drugs industry is expected to benefit from declining costs. New product launches provide some respite to AMPH, RDY and TEVA.
Amphastar Pharmaceuticals (AMPH) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
The latest trading day saw Amphastar Pharmaceuticals (AMPH) settling at $55.45, representing a -0.84% change from its previous close.
Centene (CNC) Chosen to Serve New Hampshire's Medicaid Members
by Zacks Equity Research
Centene's (CNC) subsidiary has been selected by the DHHS to serve the diversified health needs of members of New Hampshire's Medicaid program and thereby, earn more members.
Amphastar Pharmaceuticals (AMPH) Gains As Market Dips: What You Should Know
by Zacks Equity Research
The latest trading day saw Amphastar Pharmaceuticals (AMPH) settling at $56.14, representing a +1.15% change from its previous close.
Centene (CNC) Sells Circle Health to Boost Managed Care Business
by Zacks Equity Research
Centene (CNC) concludes the divestiture of Circle Health to expand its core Managed Care business. Additionally, its plan members will enjoy continued access to Kroger's pharmacy network in 2024.
Snap these 4 Top-Ranked Liquid Stocks to Drive Solid Returns
by Vaishali Doshi
Here are four top-performing liquid stocks, American Public Education (APEI), Amphastar Pharmaceuticals (AMPH), GigaCloud (GCT) and Oceaneering International (OII), which investors can add to their portfolio to boost returns.
Amphastar Pharmaceuticals (AMPH) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
Amphastar Pharmaceuticals (AMPH) concluded the recent trading session at $54.03, signifying a -1.44% move from its prior day's close.
Acadia Healthcare (ACHC) Inks JV to Better Serve Texas Residents
by Zacks Equity Research
Acadia Healthcare (ACHC) enters into a JV with Ascension Seton to expand the availability of inpatient behavioral beds across Austin and thereby, establish a solid footprint in the region.
Amphastar Pharmaceuticals (AMPH) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
Amphastar Pharmaceuticals (AMPH) concluded the recent trading session at $62.74, signifying a -1.12% move from its prior day's close.
Amphastar Pharmaceuticals (AMPH) Is Up 1.53% in One Week: What You Should Know
by Zacks Equity Research
Does Amphastar Pharmaceuticals (AMPH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here's Why You Should Retain Centene (CNC) Stock For Now
by Zacks Equity Research
Centene (CNC) remains well-poised for growth on the back of overall membership growth, acquisitions, business streamlining efforts and a growing cash balance.
4 Promising Liquid Stocks to Boost Your Portfolio in 2024
by Vaishali Doshi
Here are four top-ranked liquid stocks, Puma Biotechnology (PBYI), Amphastar Pharmaceuticals (AMPH), Vimeo (VMEO) and Fluor Corporation (FLR), which investors can add to their portfolio for solid gains
Are Medical Stocks Lagging Arch Therapeutics (ARTH) This Year?
by Zacks Equity Research
Here is how Arch Therapeutics, Inc. (ARTH) and Amphastar Pharmaceuticals (AMPH) have performed compared to their sector so far this year.
Wall Street Analysts Think Amphastar (AMPH) Is a Good Investment: Is It?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Amphastar (AMPH). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics
by Zacks Equity Research
Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics are part of the Zacks top Analyst Blog.
Zacks.com featured highlights include Amphastar Pharmaceuticals, Shift4 Payments, Beacon Roofing Supply, Hooker Furnishings and Hilltop Holdings
by Zacks Equity Research
Amphastar Pharmaceuticals, Shift4 Payments, Beacon Roofing Supply, Hooker Furnishings and Hilltop Holdings are part of the Zacks Screen of the Week article.
Tenet Healthcare (THC) Gains 60% in a Year: More Room to Run?
by Zacks Equity Research
Diversified treatment network, solid patient volumes in the Hospital segment and robust cash flows continue to drive Tenet Healthcare (THC).
What Awaits These 4 Drug Stocks That More Than Doubled in 2023?
by Ahan Chakraborty
Here are four drug, biotech stocks, AMPH, DERM, CNTA & AQST, which have more than doubled in 2023 with room for further growth in 2024.